Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HOLX 
Hologic Inc (HOLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: HOLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $73.4
1 Year Target Price $73.4
| 3 | Strong Buy |
| 3 | Buy |
| 14 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.56% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.82B USD | Price to earnings Ratio 27.64 | 1Y Target Price 73.4 |
Price to earnings Ratio 27.64 | 1Y Target Price 73.4 | ||
Volume (30-day avg) 20 | Beta 0.49 | 52 Weeks Range 51.90 - 84.39 | Updated Date 08/28/2025 |
52 Weeks Range 51.90 - 84.39 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.79% | Operating Margin (TTM) 25.48% |
Management Effectiveness
Return on Assets (TTM) 6.69% | Return on Equity (TTM) 11.38% |
Valuation
Trailing PE 27.64 | Forward PE 14.62 | Enterprise Value 15460972566 | Price to Sales(TTM) 3.67 |
Enterprise Value 15460972566 | Price to Sales(TTM) 3.67 | ||
Enterprise Value to Revenue 3.83 | Enterprise Value to EBITDA 14.17 | Shares Outstanding 222419008 | Shares Floating 220388594 |
Shares Outstanding 222419008 | Shares Floating 220388594 | ||
Percent Insiders 0.86 | Percent Institutions 101.12 |
Upturn AI SWOT
Hologic Inc
Company Overview
History and Background
Hologic Inc. was founded in 1985. Initially focused on bone densitometry, it expanded through strategic acquisitions into women's health, breast health, and diagnostics.
Core Business Areas
- Breast Health: Develops and manufactures mammography and breast biopsy systems.
- Diagnostics: Provides diagnostic tests for women's health, including molecular diagnostics for infectious diseases and cytology.
- Gynecological Surgical: Offers minimally invasive surgical solutions for women's health conditions, focusing on fibroid removal and hysteroscopy.
- Skeletal Health: Offers bone densitometry systems for osteoporosis assessment.
Leadership and Structure
Scott White serves as the CEO. The organizational structure is typical of a large publicly traded company, with functional departments and business unit leadership.
Top Products and Market Share
Key Offerings
- Genius 3D Mammography: 3D mammography system for breast cancer screening. Estimated market share in the US is approximately 40-50% in the 3D mammography market. Key competitors include Siemens Healthineers, GE Healthcare, and Fujifilm.
- Aptima HPV Assay: HPV testing for cervical cancer screening. Market share in the US is approximately 30%. Competitors include Roche and BD.
- MyoSure System: Hysteroscopic tissue removal system for uterine fibroids. Competitors include Medtronic, Boston Scientific, and Stryker.
Market Dynamics
Industry Overview
The medical device and diagnostics industry is characterized by innovation, regulation, and increasing demand due to aging populations and advancements in healthcare technology.
Positioning
Hologic is a leading player in women's health, focusing on innovative solutions in breast health, diagnostics, and surgical procedures. Its competitive advantage lies in its established brand, strong market presence, and innovative product portfolio.
Total Addressable Market (TAM)
The global women's health market is projected to reach hundreds of billions of USD. Hologic is positioned well to address a significant portion of this market, particularly in developed countries, through innovation and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Established market position in women's health
- Innovative product portfolio
- Recurring revenue streams from diagnostic testing
- Strong financial performance
Weaknesses
- Reliance on regulatory approvals
- Exposure to competition from larger medical device companies
- Potential for product liability claims
- Concentration of revenue in specific product lines
- Vulnerable to healthcare spending cuts
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests and therapies
- Strategic acquisitions to broaden product offerings
- Increased focus on personalized medicine
- Leveraging digital health solutions
Threats
- Increased competition from existing and new players
- Changes in healthcare regulations and reimbursement policies
- Technological obsolescence
- Economic downturns
- Product recalls
Competitors and Market Share
Key Competitors
- ROCHE HOLDING PTADR (RHHBY)
- SIEMENS (SIEGY)
- GENERAL ELECTRIC (GE)
Competitive Landscape
Hologic competes with a mix of large, diversified medical device companies and smaller, specialized players. Its advantages include a strong brand, innovative products, and established market position. Its disadvantages include exposure to competition from larger companies with greater resources.
Major Acquisitions
Cynosure
- Year: 2017
- Acquisition Price (USD millions): 1650
- Strategic Rationale: Expanded Hologic's presence in the medical aesthetics market.
Growth Trajectory and Initiatives
Historical Growth: Hologic has experienced strong historical growth, driven by acquisitions and organic growth in its core business segments.
Future Projections: Analysts project continued growth in revenue and earnings, driven by demand for women's health solutions and expansion into new markets.
Recent Initiatives: Recent strategic initiatives include acquisitions of companies in complementary markets and investments in R&D to develop new products and technologies.
Summary
Hologic is a solid company with a strong position in the women's health market. Its innovative product portfolio and brand recognition are working well, leading to positive growth. Reliance on regulatory approvals and increased competition are issues Hologic needs to monitor. Strategic acquisitions will further improve its competitive advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and company performance are subject to change. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hologic Inc
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1990-06-21 | Chairman, CEO & President Mr. Stephen P. MacMillan | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 7063 | Website https://www.hologic.com |
Full time employees 7063 | Website https://www.hologic.com | ||
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.